SAT0453 Efficacy of Ustekinumab in Psoriatic Arthritis Patients by Prior Treatment Exposure and Disease Duration: Data From Psummit 1 and Psummit 2

doi 10.1136/annrheumdis-2017-eular.4538
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Clinical pharmacology and therapy
2018English

AB0760 Efficacy of Ustekinumab in a Cohort of Patients Affected by Psoriatic Arthritis in Real-Life

2017English

The Duration of Remission and Minimal Disease Activity After Initiation and Discontinuation of Biological Agents in Patients With Early Psoriatic Arthritis (Data From the All-Russian Psoriatic Arthritis Registry)

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2019English

Correction To: Drug Survival and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis. Real-Life Data From the Biologic Apulian Registry (BIOPURE)

Clinical Rheumatology
MedicineRheumatology
2018English

Efficacy and Safety of Intravenous Golimumab Through 1 Year in Patients With Active Psoriatic Arthritis

Arthritis Care and Research
Rheumatology
2019English

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

Gastroenterology
HepatologyGastroenterology
2018English

Disease Activity and Related Variables in Patients With Psoriatic Arthritis

Archives of Rheumatology
Rheumatology
2014English

FRI0508 the Effect of Certolizumab Pegol on Extra-Articular Manifestations of Psoriatic Arthritis Over 4 Years of Treatment in Patients With and Without Prior Anti-TNF Exposure

2017English

Clinical Experience of Cyclosporin Treatment in Patients With Psoriasis and Psoriatic Arthritis

Journal of Dermatology
DermatologyMedicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy